Literature DB >> 19889794

Antitumorigenic effects of cannabinoids beyond apoptosis.

Nadine Freimuth1, Robert Ramer, Burkhard Hinz.   

Abstract

According to the World Health Organization, the cases of death caused by cancer will have been doubled until the year 2030. By 2010, cancer is expected to be the number one cause of death. Therefore, it is necessary to explore novel approaches for the treatment of cancer. Over past years, the antitumorigenic effects of cannabinoids have emerged as an exciting field in cancer research. Apart from their proapoptotic and antiproliferative action, recent research has shown that cannabinoids may likewise affect tumor cell angiogenesis, migration, invasion, adhesion, and metastasization. This review will summarize the data concerning the influence of cannabinoids on these locomotive processes beyond modulation of cancer cell apoptosis and proliferation. The findings discussed here provide a new perspective on the antitumorigenic potential of cannabinoids.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19889794     DOI: 10.1124/jpet.109.157735

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  25 in total

Review 1.  Monoacylglycerol lipase - a target for drug development?

Authors:  C J Fowler
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

Review 2.  A Double Whammy: Targeting Both Fatty Acid Amide Hydrolase (FAAH) and Cyclooxygenase (COX) To Treat Pain and Inflammation.

Authors:  Rita Scarpelli; Oscar Sasso; Daniele Piomelli
Journal:  ChemMedChem       Date:  2015-10-21       Impact factor: 3.466

3.  Cannabidiol inhibits angiogenesis by multiple mechanisms.

Authors:  M Solinas; P Massi; A R Cantelmo; M G Cattaneo; R Cammarota; D Bartolini; V Cinquina; M Valenti; L M Vicentini; D M Noonan; A Albini; D Parolaro
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

Review 4.  Cannabidiol as potential anticancer drug.

Authors:  Paola Massi; Marta Solinas; Valentina Cinquina; Daniela Parolaro
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

5.  Cannabinoid receptor type 1 (CB1) activation inhibits small GTPase RhoA activity and regulates motility of prostate carcinoma cells.

Authors:  Kasem Nithipatikom; Ana Doris Gomez-Granados; Alan T Tang; Adam W Pfeiffer; Carol L Williams; William B Campbell
Journal:  Endocrinology       Date:  2011-11-15       Impact factor: 4.736

6.  Decrease of plasminogen activator inhibitor-1 may contribute to the anti-invasive action of cannabidiol on human lung cancer cells.

Authors:  Robert Ramer; Anja Rohde; Jutta Merkord; Helga Rohde; Burkhard Hinz
Journal:  Pharm Res       Date:  2010-07-29       Impact factor: 4.200

Review 7.  The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids.

Authors:  Sean D McAllister; Liliana Soroceanu; Pierre-Yves Desprez
Journal:  J Neuroimmune Pharmacol       Date:  2015-04-28       Impact factor: 4.147

8.  Cannabinoids as anticancer therapeutic agents.

Authors:  Olga Kovalchuk; Igor Kovalchuk
Journal:  Cell Cycle       Date:  2020-04-05       Impact factor: 4.534

9.  Population-based case-control study of recreational drug use and testis cancer risk confirms an association between marijuana use and nonseminoma risk.

Authors:  John Charles A Lacson; Joshua D Carroll; Ellenie Tuazon; Esteban J Castelao; Leslie Bernstein; Victoria K Cortessis
Journal:  Cancer       Date:  2012-09-10       Impact factor: 6.860

10.  Association between cannabinoid CB₁ receptor expression and Akt signalling in prostate cancer.

Authors:  Mariateresa Cipriano; Jenny Häggström; Peter Hammarsten; Christopher J Fowler
Journal:  PLoS One       Date:  2013-06-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.